Background
Leukocyte-associated immunoglobulin like receptor-1 (LAIR1) is a transmembrane inhibitory receptor that influences susceptibility to a myriad of inflammatory diseases. Our recent investigations of severe malarial anaemia (SMA) pathogenesis in Kenyan children discovered that novel
LAIR1
genetic variants which were associated with decreased
LAIR1
transcripts enhanced the longitudinal risk of SMA and all-cause mortality.
Methods
To characterize the molecular mechanism(s) responsible for altered
LAIR1
signalling in severe malaria, we determined LAIR1 transcripts and protein, sLAIR1, sLAIR2, and complement component 1q (C1q) in children with malarial anaemia, followed by a series of
in vitro
experiments investigating the LAIR1 signalling cascade.
Findings
Kenyan children with SMA had elevated circulating levels of soluble LAIR1 (sLAIR1) relative to non-SMA (1.69-fold
P
< .0001). The LAIR1 antagonist, sLAIR2, was also elevated in the circulation of children with SMA (1.59 fold-change,
P
< .0001). There was a positive correlation between sLAIR1 and sLAIR2 (ρ = 0.741,
P
< .0001). Conversely, circulating levels of complement component 1q (C1q), a LAIR1 natural ligand, were lower in SMA (−1.21-fold
P
= .048). These
in vivo
findings suggest that reduced membrane-bound LAIR1 expression in SMA is associated with elevated production of sLAIR1, sLAIR2 (antagonist), and limited C1q (agonist) availability. Since reduced
LAIR1
transcripts in SMA were associated with increased acquisition of haemozoin (
Pf
Hz) by monocytes (
P
= .028), we explored the relationship between acquisition of intraleukocytic
Pf
Hz,
LAIR1
expression, and subsequent impacts on leukocyte signalling in cultured PBMCs from malaria-naïve donors stimulated with physiological concentrations of
Pf
Hz (10 μg/mL). Phagocytosis of
Pf
Hz reduced
LAIR1
transcript and protein expression in a time-dependent manner (
P
< .050), and inhibited LAIR1 signalling through decreased phosphorylation of LAIR1 (
P
< .0001) and SH2-domain containing phosphatase-1 (SHP-1) (
P
< .001). This process was associated with NF-κB activation (
P
< .0001) and enhanced production of IL-6, IL-1β, and TNF-α (all
P
< .0001).
Interpretation
Collectively, these findings demonstrate that SMA is characterized by reduced LAIR1 transmembrane expression, reduced C1q, and enhanced production of sLAIR1 and s...